The erythromycin breath test as a predictor of cyclosporine blood levels

[1]  P. Watkins,et al.  Identification of a polymorphically expressed member of the human cytochrome P-450III family. , 1989, Molecular pharmacology.

[2]  J. Bach.  Cyclosporine in autoimmune diseases. , 1989, Transplantation proceedings.

[3]  J. Derancourt,et al.  Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[4]  B. Kahan,et al.  Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. , 1988, Transplantation.

[5]  T. Kronbach,et al.  Cyclosporine metabolism in human liver: Identification of a cytochrome P‐450III gene family as the major cyclosporine‐metabolizing enzyme explains interactions of cyclosporine with other drugs , 1988, Clinical pharmacology and therapeutics.

[6]  R. Margreiter,et al.  Rigid-dose regimen versus blood level-adjusted cyclosporine in elderly cadaveric renal allograft recipients. , 1988, Transplantation proceedings.

[7]  C. Cheney,et al.  Effect of obesity on cyclosporine disposition. , 1988, Transplantation.

[8]  C. F. Anderson,et al.  Cyclosporine nephrotoxicity is minimized by adjusting dosage on the basis of drug concentration in blood. , 1988, Mayo Clinic proceedings.

[9]  P. Watkins,et al.  Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rats. , 1987, The Journal of clinical investigation.

[10]  P. Watkins,et al.  Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. , 1987, The Journal of clinical investigation.

[11]  R. Branch,et al.  Genetically determined polymorphisms in drug oxidation , 1986, Hepatology.

[12]  T. Annesley,et al.  Liquid-chromatographic analysis for cyclosporine with use of a microbore column and small sample volume. , 1986, Clinical chemistry.

[13]  D. Waxman,et al.  Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. , 1986, The Journal of biological chemistry.

[14]  C. V. van Buren,et al.  DEMOGRAPHIC FACTORS AFFECTING THE PHARMACOKINETICS OF CYCLOSPORINE ESTIMATED BY RADIOIMMUNOASSAY , 1986, Transplantation.

[15]  J. Crowley,et al.  CORRELATION OF SERUM CYCLOSPORINE CONCENTRATION WITH RENAL DYSFUNCTION IN MARROW TRANSPLANT RECIPIENTS , 1985, Transplantation.

[16]  P. Watkins,et al.  Identification of an inducible form of cytochrome P-450 in human liver. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Tilg,et al.  CYCLOSPORIN BLOOD LEVELS DO CORRELATE WITH CLINICAL COMPLICATIONS , 1984, The Lancet.

[18]  D. Schoeller,et al.  Clinical diagnosis with the stable isotope 13C in CO2 breath tests: methodology and fundamental considerations. , 1977, The Journal of laboratory and clinical medicine.

[19]  F. Guengerich.  Characterization of human microsomal cytochrome P-450 enzymes. , 1989, Annual review of pharmacology and toxicology.

[20]  P. de Groen.  Cyclosporine, low-density lipoprotein, and cholesterol. , 1988, Mayo Clinic proceedings.

[21]  W. Bennett,et al.  Cyclosporine nephrotoxicity. , 2003, Seminars in nephrology.